FBR Capital Downgrades Galectin Therapeutics (GALT) to Market Perform

October 3, 2016 6:23 AM EDT
Get Alerts GALT Hot Sheet
Price: $0.80 -1.23%

Rating Summary:
    2 Buy, 3 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 26 | Down: 29 | New: 38
Trade GALT Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

FBR Capital downgraded Galectin Therapeutics (NASDAQ: GALT) from Outperform to Market Perform with a price target of $2.00 (from $12.00).

Analyst Vernon Bernardino commented, "On September 27, Galectin Therapeutics announced that NASH-FX had failed to meet its primary and secondary endpoints. The study was one of two ongoing Phase II clinical trials to evaluate GALT’s galectin-3 inhibitor drug candidate, GRMD-02, in patients with non-alcoholic steatohepatitis (NASH). Only top-line results for safety, tolerability, and the endpoints not met were announced, making it hard to draw conclusions whether there are ramifications for the second trial, NASHCX (cirrhosis). However, as the next major catalyst from the company is likely the announcement of top-line results from NASH-CX, which is anticipated in December 2017, we think current prices of GALT stock reflect a balance between its upside potential and downside risk over the next 12 months. As a result, we lower our rating from Outperform to Market Perform and lower our estimate for fair value of the shares from $12 to $2. We continue to like GALT’s prospects for creating value with the advancement of GR-MD-02 in NASH cirrhosis and look to further details from NASH-FX before revisiting our investment opinion."

For an analyst ratings summary and ratings history on Galectin Therapeutics click here. For more ratings news on Galectin Therapeutics click here.

Shares of Galectin Therapeutics closed at $1.13 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change, Downgrades

Add Your Comment